« October 2006 | Main | December 2006 »

Nov29
AEterna Zentaris’ AN-152 Successfully Passed Phase 1 Clinical Trial in Gynaecological and Breast Cancers Patients

AEterna Zentaris Inc. (TSE: AEZ; NASDAQ: AEZS) recently announced the additional positive top line Phase 1 results for its cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers.

Clinical data revealed the compound's good safety profile and established the maximum tolerated dose (MTD) at 267 mg/m(2) which will be the recommended dose for a Phase 2 trial.

Aeterna_Zentaris.jpgThe said trial also provided a hint of efficacy as disease stabilization and regression of lesions were observed at the 160 mg/m(2) and 267 mg/m(2) dose levels.

Find more details from the press release.

[Note: I don't undertand the unit: mg/m(2). is that mg per m squared (square meter)? Square meter of what? Surface area? or should it be mg/ml referring to the concentration/volume of the compound? or should it be mm as in millimeter?]

Nov29
Cytogen Received US Patent Covering Oral Drug Delivery Agents
Anesiva Submitted USFDA NDA for Zingo™ (Pain Reliever for Needle Insertion Procedures in Children)
Nov28
MannKind Corporation’s IND for MKC1106-PP Immunotherapy in Solid Malignancies, USFDA-Cleared
Mayne Pharma Acquired Remaining Rights to SuperGen Inc.’s Nipent®
Melbourne-Based Biota Closed US$102 Million License with Boehringer Ingelheim for Hepatitis C Virus (HCV) Program
Cytokinetics and GlaxoSmithKline Amend Ispinesib (SB-715992) and SB-743921 Collaboration and License Agreement
Betaferon® Approved in Australia for Early Stage Multiple Sclerosis (MS)
DRAXIS Radiopharmaceutical Unit, DRAXIMAGE: Received USFDA Approval to Run 2 Clinical Trials for Neuroblastoma Treatment
Nov27
AstraZeneca Entered Distribution Agreement With Par Pharmaceutical for Authorized Generic TOPROL-XL® (metoprolol succinate)
Back from "Thanksgiving" Weekend
Nov22
Artemis Agreed With Merck & Co., Inc. In making Genetically Engineered In-Vivo RNAi Mouse Models
PARI and Kamada Collaboration will Develop Inhaled Alpha-1 Antitrypsin (AAT)
GlaxoSmithKline, To Supply U.S. Stockpile with bulk H5N1 Antigen
Sanofi Pasteur, In Contract with the U.S. Government for Stockpile of New Type (clade 2) of H5N1 Pre-Pandemic Vaccine
Nov21
BioCryst's Anti-Cancer Drug Fodosine™ Received Orphan Status In Europe
Pharmacyclics’ Xcytrin® Showed Positive Phase III Trials in Lung Cancer Brain Metastasis
Target Hemoglobin Range in Most Anemic Chronic Kidney Disease Pre-Dialysis Patients Achieved With PROCRIT® (Epoetin alfa) Therapy Initiated Every Two Weeks
Nov20
NPRL2: Introgen’s Novel Nanoparticle Tumor Suppressor Reverses Resistantce to Cisplatin in Lung Cancer Treatment
Somaxon Pharmaceuticals' SILENOR™ Passed Phase III Insomnia Clinical Trial
Nov19
Update on XERECEPT® for Peritumoral Brain Edema, Presented by Celtic Pharma and Neurobiological Technologies at SNO Annual Meeting
Shire’s Investigational Drug for Adult ADHD: SPD465, Bioequivalent to ADDERALL XR
Nov18
Genentech’s Herceptin® USFDA Approved for Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Nov17
Advanced Magnetics’ Ferumoxytol as an Intravenous Iron Replacement Therapeutic, Passed Phase III Clinical Trial
Novalar Pharmaceuticals’ Local Dental Anesthetic Reversal Agent (NV-101) Passed Phase 2 Clinical Trial in Pediatric Population
Pfizer Animal Health Agreed to Acquire Embrex, Inc.
Novel Intranasal Analgesic, ROXRO Pharma’s Ketorolac (ROX-888): Provides Effective Pain Relief
Vanda Pharmaceuticals' VEC-162 Passed Phase III Clinical Trial on Transient Insomnia
WelChol® (colesevelam HCl) +Insulin Improves Glycemic Control Uncontrolled Type 2 Diabetes Mellitus Patients: New Study Confirms
Nov16
Intensive Lipitor Therapy Reduced Heart Attack and Stroke By One-Third in Chronic Kidney Disease Patients: First Dose-Dependent Lipitor Data Analysis Revealed
Dangerous Pill: New NABP Anti-Counterfeit Drug Website
Nov15
AIDS Healthcare Foundation and CIPLA Discussed Drug Price Reduction Issue in India
Alba Therapeutics’ Oral Zonulin Receptor (AT-1001) Passed Phase Ib Clinical Trial on Celiac Disease
Secondary Endpoint Not Met in Favrille’s Phase 3 Clinical Trial of FavId® Following Rituxan® in Follicular B-Cell Non-Hodgkin's Lymphoma (NHL)
Nov14
Roche’s ACTEMRA™ (tocilizumab) Significantly Improved Remission Rates in Rheumatoid Arthritis Patients
New Study Data Revealed that Lilly’s Ruboxistaurin (Arxxant™) Reduced Vision Loss in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy (DR)
Immunomedics Reported Epratuzumab and Rituximab Modes of Action at the ACR Annual Meeting
New Study Further Supports Cardiovascular Safety of Over-The-Counter (OTC) Doses of Naproxen Sodium
Nov13
Use of Thymoglobulin® is Beneficial than Basiliximab in kidney Transplant Patients
Pharmacyclics’s Phase 2 Clinical Trial of Xcytrin® With Radiosurgery for Brain Metastases, Showed Positive Results
Boehringer Ingelheim‘s Mirapex®: USFDA-Approved fro the Treatment of Restless Legs Syndrome (RLS)
Angiotech's Vascular Wrap™ Passed First Human Trial
Nov 9
Bavarian Nordic Reported Progress in New Smallpox Vaccine Program
Perrigo Co. Recalls 11 Million Acetaminophen Bottles
Anadys Pharma’s ANA975 Under New 13-Week Pre-Clinical Toxicology Study Using Crystalline Form
NUVIGIL™ Composition of Matter Patent, Granted to Cephalon, Inc.
Metabolex Received European Patent for Metaglidasen
Infinity and MedImmune’s Anti-Hsp90 Compound: IPI-504, Showing Promising Biological Activity in Phase I Trial in Gastrointestinal Stromal Tumors (GIST)
QUADRAMET®’s Combination Study in High-Risk Prostate Cancer Patients, Passed Phase 1 Clinical Trial
TK Sense(SM): Panacea Pharmaceuticals' Test that Predicts Response to Imatinib (Gleevec®) Therapy in Chronic Myelogenous Leukemia (CML)
Nov 8
PharmaGazette is The PharmVoice No More
Nov 7
Special Protocol Assessment (SPA) Approval, Granted by USFDA for Gamida Cell's Stemex® Registration Study
Acquisition of Kos Pharmaceuticals Will Expand Abbott’s Presence in the Lipid Management Market
Celgosivir Combination Therapy, Clinically Beneficial in Chronic Hepatitis C Non-Responder Patients
Poniard’s Picoplatin, Showing Positive Interim Survival Results from Ongoing Phase 2 Trial for Small Cell Lung Cancer
Two Randomized Clinical Trials of ERBITUX® in Metastatic Colorectal Cancer, Revealed Survival Data
Nov 6
Introgen Therapeutics Gained Exclusive License to Therapies Combining Epidermal Growth Factor (EGFr) Drugs and Tumor Suppressor Genes
2006 Thomas Alva Edison Patent Award for Potential New Therapy for the Prevention of Osteoporosis, Awarded to Wyeth Researchers
Ispinesib Clinical Data and SB-743921 Non-Clinical Data: To be Presented by Cytokinetics at the 2006 EORTC-NCI-AACR International Meeting
LEVITRA® Effectively Treated Erectile Dysfunction (ED) at First Dose In Men With Certain Associated Cardiovascular Conditions, New Clinical Data Revealed
Nov 5
WHO is Launching IMPACT (International Medical Products Anti-counterfeiting Taskforce): A Global Anti-Counterfeiting Plan
CuraGen and TopoTarget Out-Licensed Worldwide Rights of PXD118490 (Preclinical HDAC Inhibitor) To LEO Pharma
US National Institutes of Health Picked Evogenix For Anti-Cancer Collaboration
Inyx, Inc. Sealed Deal with Plethora Solutions for the Production of Novel HFA Aerosol (Treatment for Premature Ejaculation) for U.S. Clinical Trial
AstraZeneca’s Revised Patient Assistance Program Aims to Help More People Afford Its Medicines
Oramed Pharmaceuticals Signed Manufacturing Agreement with Swiss Caps AG
Nov 4
Ranbaxy Received Tentative USFDA Approval to Manufacture and Market Cetirizine Hydrochloride Syrup
BioMS Medical Receives Additional US Patent for MS Drug MBP8298
Three New Mycobacterial Cell Wall-DNA Complex (MCC), Granted to Bioniche Life Sciences
Osteologix Received European Patent for the Treatment of Cartilage and Bone Conditions
Lpath and Sapient Discovery’s Collaborative Study That Characterized Favorable Interactions of Lpath's Anti-S1P Therapeutic Antibody with Its Target, Successfully Completed
InViragen and Shantha Biotechnics Entered Into Dengue Vaccine Manufacturing Agreement
Nov 3
61.5 % of Study Participants Experienced Hair Regrowth Using the Natural Supplement Nourkrin®
Lorus Therapeutics Presented GTI-2040 Pharmacokinetic in Acute Myeloid Leukemia at the AAPS Meeting
CVS Corporation Merges with and Caremark Rx, Inc.
Nov 1
China Pharma Granted GMP Certification and SFDA Approval for the Production of Cephalosporin
Dong-A Pharmaceutical Co., Ltd. Agreed with SCP (Saudi Arabia) for the Distribution of Erectile Dysfunction Drug Zydena in (Gulf Cooperation Council) Countries

« October 2006 | Main | December 2006 »

Advertise

Watch the Digital Health Revolution


sponsored ads



Incredible Hall of Acclaim.

subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

WebMetricsGuru

TheInsurancePolicy

MarketingBlurb